These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 23248795)

  • 1. Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.
    Coffin CS; Fung SK; Ma MM;
    Can J Gastroenterol; 2012 Dec; 26(12):917-38. PubMed ID: 23248795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.
    Tang CM; Yau TO; Yu J
    World J Gastroenterol; 2014 May; 20(20):6262-78. PubMed ID: 24876747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current trends in chronic hepatitis B management: results of a questionnaire.
    Les I; García-Martínez R; Córdoba J; Quintana M; Esteban R; Buti M
    Eur J Gastroenterol Hepatol; 2009 Oct; 21(10):1177-83. PubMed ID: 19430301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update in the management of chronic hepatitis B.
    Tujios SR; Lee WM
    Curr Opin Gastroenterol; 2013 May; 29(3):250-6. PubMed ID: 23519135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.
    Fung J; Chan SC; Cheung C; Yuen MF; Chok KS; Sharr W; Chan AC; Cheung TT; Seto WK; Fan ST; Lai CL; Lo CM
    Am J Gastroenterol; 2013 Jun; 108(6):942-8. PubMed ID: 23629601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection.
    Buster EH; Baak BC; Bakker CM; Beuers UH; Brouwer JT; Drenth JP; van Erpecum KJ; van Hoek B; Honkoop P; Kerbert-Dreteler MJ; Koek GH; van Nieuwkerk KM; van Soest H; van der Spek BW; Tan AC; Vrolijk JM; Janssen HL
    Neth J Med; 2012 Oct; 70(8):381-5. PubMed ID: 23065990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of combination therapy in chronic hepatitis B.
    Scott JD; McMahon B
    Curr Gastroenterol Rep; 2009 Feb; 11(1):28-36. PubMed ID: 19166656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical management of patients with chronic hepatitis B virus infection].
    Rodríguez M; González-Diéguez ML
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():56-65. PubMed ID: 19100232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management and treatment of chronic hepatitis B virus: Belgian Association for the Study of the Liver (BASL) 2007 guidelines.
    Colle I; Adler M; Brenard R; Henrion J; Langlet P; Michielsen P; Orlent H; Reynaert H; Sprengers D; Stärkel P; Van Damme P; Verslype C; Delwaide J;
    Acta Gastroenterol Belg; 2007; 70(4):389-420. PubMed ID: 18330099
    [No Abstract]   [Full Text] [Related]  

  • 11. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
    Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
    Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Liver transplantation for complications of hepatitis B].
    Roche B; Samuel D
    Presse Med; 2006 Feb; 35(2 Pt 2):335-45. PubMed ID: 16493338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Hadziyannis SJ
    Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New advances in chronic hepatitis B.
    Tujios SR; Lee WM
    Curr Opin Gastroenterol; 2012 May; 28(3):193-7. PubMed ID: 22450894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interdisciplinary aspects of and new drugs for chronic hepatitis B].
    Horváth G
    Orv Hetil; 2013 Jul; 154(29):1142-50. PubMed ID: 23853347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.
    Chae HB; Kim MJ; Seo EG; Choi YH; Lee HS; Han JH; Yoon SM; Park SM; Youn SJ
    Korean J Hepatol; 2012 Mar; 18(1):75-83. PubMed ID: 22511906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B: explosion of new knowledge.
    Keeffe EB
    Gastroenterology; 2007 Nov; 133(5):1718-21. PubMed ID: 17983813
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.